Macular Degeneration Treatment Market Size, Top Share, Forecast To 2033

(MENAFN- Straits Research) Introduction

The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of central vision because it gives the clear main idea required to see objects. It manifests when the capillaries close to the fovea enlarge and leak. The fluid buildup interferes with light reflection, which causes progressive vision loss. Nutritional therapy can aid treatment in the early stages of dry macular degeneration. A healthy diet rich in antioxidants is part of the plan to sustain the macula's cells.

Market Dynamics Rising Impact of Retinal Disorder Drivers on the Global Market

The rising prevalence of retinal diseases has increased the demand for macular degeneration treatment . Eye conditions have emerged as potential threats in many developed and developing countries. Globally, the prevalence of the most severe eye conditions is rising, and vision loss is becoming a serious public health concern. Numerous worldwide retinal diseases that impair vision have been identified by the World Health Organization (WHO). Two of these conditions, refractive errors, and age-related macular disorders, are most prevalent in underdeveloped countries. As a result of the rising prevalence of retinal disorders, it is anticipated that the market for treating macular degeneration will expand significantly over the forecast period.

According to the UN's World Aging Report, 703 million individuals were 65 or older in 2019. By 2050, this number is anticipated to double. The population aged 65 and older increased globally from 6% in 1990 to 9% in 2019. Smart contact lenses and intelligent optometry are two examples of cutting-edge and digital healthcare products that may impact the market under consideration. Future developments in digital technology could affect eye care. Future access to gene chips could lead to more accurate AMD and glaucoma diagnosis and treatment. Due to investments made by businesses and accelerated research, the market is anticipated to grow during the forecast period.

Regional Analysis

North America is the most significant shareholder in the global macular degeneration treatment market and is expected to grow at a CAGR of 7.10% during the forecast period. The United States represents a sizable portion of the market under study due to several factors, including the burden of the aging population and the prevalence of age-related macular degeneration. The US is dedicated to improving overall population eye health through several initiatives. Along with recent product launches and established healthcare infrastructure, it is also anticipated that the presence of the major market players will hasten the market's expansion in the United States. Novel macular degeneration treatments are expected to fuel market growth in the United States.

Europe is expected to grow at a CAGR of 6.70%, generating USD 3,531.14 million during the forecast period. The aging population, the rising prevalence of macular degeneration, and sizable R&D expenditures are additional factors influencing the expansion of the French market under investigation. In France, there are an increasing number of cutting-edge research studies being carried out. The funding provided by the government, both at the national and EU agency levels, is primarily to blame. Medical costs are covered by the government and the individual in France, which has one of the best healthcare systems. Over the anticipated period, it is anticipated that these campaigns will increase public awareness and spur rapid market growth in France.

The presence of significant market players, the rising elderly population in Japan, and the rising awareness of macular degeneration in Asia-Pacific all point to a substantial expansion of the Japanese market for macular degeneration treatments. Japan is one of the Asian countries that is aging quickly. In June 2019, Sumitomo Dainippon Pharma Co. Ltd. modified its contract with Healios K.K. for joint development initiatives and other cooperative activities in Japan. The modifications concerned the activities of development and commercialization. Joint development activities will generate retinal pigment epithelial cells from iPS cells to treat age-related macular degeneration and other eye diseases. Due to the rising AMD prevalence and research and development efforts in the area, the market for macular degeneration treatments in Japan is anticipated to increase.

Key Highlights

• The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach from USD 10.77 billion in 2025 to USD 18.59 Billion by 2033, growing at a CAGR of 7.06% during the forecast period (2025–2033).

• Based on type, the global macular degeneration treatment market is bifurcated into dry and wet age-related macular degeneration. The wet age-related macular degeneration segment is the highest contributor to the market and is expected to grow at a CAGR of 6.98% over the forecast period.
• Based on the stage of disease, the global macular degeneration treatment market is bifurcated into early-stage AMD, intermediate AMD, and late-stage AMD. The late-stage AMD segment owns the highest market share and is expected to grow at a CAGR of 7.03% during the forecast period.
• Based on the route of administration, the global macular degeneration treatment market is bifurcated into the intravenous route and intravitreal route. The intravitreal route segment is the highest contributor to the market and is expected to grow at a CAGR of 7.10% during the forecast period.
• Based on sales channels, the global macular degeneration treatment market is bifurcated into ambulatory surgical centers and hospitals. The hospital segment owns the highest market share and is expected to grow at a CAGR of 7.04% during the forecast period.
• North America is the most significant shareholder in the global macular degeneration treatment market and is expected to grow at a CAGR of 7.10% during the forecast period.

Competitive Players

The global macular degeneration treatment market's major key players are Novartis AG, Pfizer Inc., Panoptica, Bausch Health Companies Inc., Regeneron Pharmaceutical Inc., Aerie Pharmaceutical Inc., REGENXBIO Inc., and Bayer AG.

Market News

• In August 2022, Novartis intends to completely spin off the Sandoz division to establish a standalone business.
• In September 2022, Bayer will present new cardiorenal results for Kerendia in individuals with early-stage chronic kidney disease and type 2 diabetes (finerenone).

Global Macular Degeneration Treatment Market: Segmentation By Type

• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

• Intravenous Route
• Intravitreal Route

• Ambulatory Surgical Centers
• Hospitals
• Other Sales Channels

• North America
• Europe
• Asia-Pacific
• The Middle East and Africa
• South America

MENAFN29012025004597010339ID1109142641